Étude de la réponse immunitaire au traitement antirétroviral au cours de l'infection par le virus de l'immunodéficience humaine |
|
Impact of HIV/SIV infection and antiretroviral treatment on adipose tissue alterations : role of fibrosis and aging. |
|
Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM. |
|
Impacts de l'infection par le VIH/VIS et des antirétroviraux sur les atteintes du tissu adipeux : rôle de la fibrose et du vieillissement |
|
Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. |
|
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection |
|
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals |
|
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literature |
|
Is monotherapy maintenance the way forward? |
|
The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events |
|
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population |
|
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients |
|
Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders |
|
Lipohypertrophy and metabolic disorders in HIV patients on antiretroviral therapy: a systematic multidisciplinary clinical approach |
|
Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared |
|
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens |
|
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine |
|
Long-term immune response to yellow fever vaccination in HIV-infected individuals depends on HIV-RNA suppression status: Implications for vaccination schedule. |
|
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study |
|
Management of HIV/ AIDS in 2015 |
|
Managing Advanced HIV Disease in a Public Health Approach |
|
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection |
|
The marriage of science and optimized HIV care in resource-limited settings |
|
Mesenterial involvement of Mycobacterium genavense infection: hard to find, hard to treat |
|
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection |
|
Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field |
|
Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapy |
|
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients |
|
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017 |
|
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial |
|
A new era of antiretroviral drug toxicity. |
|
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection |
|
Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis |
|
Patient safety in medical humanitarian action : medical error prevention and management |
|
The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy. |
|
Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis |
|
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals |
|
Preferred antiretroviral drugs for the next decade of scale up. |
|
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study |
|
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy |
|
Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir. |
|
A randomized crossover study to compare efavirenz and etravirine treatment. |
|
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching |
|
Rationing antiretroviral therapy in Africa--treating too few, too late. |
|
Reasons for late presentation to HIV care in Switzerland |
|
Reduction of missed appointments at an urban primary care clinic: a randomised controlled study |
|
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir |
|
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study |
|
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). |
|
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study |
|
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study |
|
Safety and efficacy of once-daily nevirapine dosing: a multicohort study |
|
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings |
|
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis |
|
La sécurite du patient dans l’activité médicale humanitaire : prévention et gestion des erreurs médicales. |
|
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality |
|
Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. |
|
Sous l'œil de Malick Sidibé : et un chant contre le sida : [exposition, Musée Barbier-Mueller, Genève, Suisse, du 19 juin 2019 au 12 janvier 2020] ; suivi de Art millénaire du Mali |
|
Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals |
|
Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country |
|
Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population |
|
Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. |
|
Successful efavirenz dose reduction guided by therapeutic drug monitoring. |
|
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study |
|
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study |
|
Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy |
|
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment |
|
Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity |
|
Time to overcome pretreatment HIV drug resistance. |
|
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon |
|
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses |
|
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study |
|
Treatment of HIV infection with drugs for HSV-2 infection |
|
Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. |
|
Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. |
|
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients |
|
Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone |
|
Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis |
|
Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis |
|
What's new in HIV in 2014? |
|
When to start antiretroviral therapy in resource-limited settings: a human rights analysis |
|